Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched mul...
...Published in Leukemia
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia
...
Published in Leukemia
The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherapy. The effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs...
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
...
Published in Leukemia
TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Although altered TRAF6 expression is observed in human acute myeloid leukemia (AML), its role in the AML pathogenesis remains elusive. In this study, we showed that the loss of TRAF6 in AML cells significantly impairs leukemic functi...
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular featu...
...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients...
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Published in Leukemia
The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has broadened our understanding of the heterogeneous molecular basis of the disease. Since genetic sequencing has become a standard practice, several driver mutations have been identified. Accordingly, novel targeted therapeutic ag...
High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in ...
Published in Leukemia
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms
...
Published in Leukemia
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering the diversity of the HSPCs compartment may allow for the early detection of an emergent sub-clone that drives dise...
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated...
...
Published in Leukemia
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment...
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged...
...
Published in Leukemia
Infant and adult MLL1/KMT2A -rearranged (MLLr) leukemia represents a disease with a dismal prognosis. Here, we present a functional and proteomic characterization of in utero -initiated and adult-onset MLLr leukemia. We reveal that fetal MLL::ENL -expressing lymphomyeloid multipotent progenitors (LMPPs) are intrinsically programmed towards a lympho...
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance
...
Published in Leukemia
Relapse in T-cell acute lymphoblastic leukemia (T-ALL) may signify the persistence of leukemia-initiating cells (L-ICs). Ectopic TAL1/LMO expression defines the largest subset of T-ALL, but its role in leukemic transformation and its impact on relapse-driving L-ICs remain poorly understood. In TAL1 / LMO mouse models, double negative-3 (DN3; CD4−CD...
